1. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. Issue 1 (12th March 2020) Authors: Olson, Daniel J; Rajagopal, Padma; Tjota, Melissa Y; Venkataraman, Girish; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? – Authors' reply. Issue 10352 (20th August 2022) Authors: Luke, Jason J; Ibrahim, Nageatte; Eggermont, Alexander MM Journal: Lancet Issue: Volume 400:Issue 10352(2022) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer. (4th November 2015) Authors: Sweis, Randy F; Spranger, Stefani; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma. (4th November 2015) Authors: Zha, Yuanyuan; Spranger, Stefani; Hernandez, Kyle M; Li, Yan; Bao, Riyue; Alexieff, Peter; Andrade, Jorge; Luke, Jason J; Gajewski, Thomas F Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma – Authors' reply. Issue 1 (January 2023) Authors: Long, Georgina V; Luke, Jason J; Fukunaga-Kalabis, Mizuho; Ascierto, Paolo A Journal: Lancet oncology Issue: Volume 24:Issue 1(2023) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Issue 3 (14th March 2022) Authors: Naing, Aung; Powderly, John D; Nemunaitis, John J; Luke, Jason J; Mansfield, Aaron S; Messersmith, Wells A; Sahebjam, Solmaz; LoRusso, Patricia M; Garrido-Laguna, Ignacio; Leopold, Lance; Geschwindt, Ryan; Ding, Kai; Smith, Michael; Berlin, Jordan D Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 3(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. Issue 7 (16th July 2021) Authors: Bao, Riyue; Spranger, Stefani; Hernandez, Kyle; Zha, Yuanyuan; Pytel, Peter; Luke, Jason J; Gajewski, Thomas F; Volchenboum, Samuel L; Cohn, Susan L; Desai, Ami V Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. Issue 1 (14th October 2014) Authors: Ravi, Sowmya; Spencer, Kristen; Ruisi, Mary; Ibrahim, Nageatte; Luke, Jason J; Thompson, John A; Shirai, Keisuke; Lawson, David; Bartell, Heddy; Kudchadkar, Ragini; Gunter, Ngoc Thi; Mehnert, Janice M; Lipson, Evan J Journal: Journal for immunotherapy of cancer Issue: Volume 2:Issue 1(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Issue 7 (July 2019) Authors: Andrews, Miles C; Berry, Donald A; Block, Matthew S; Boland, Genevieve M; Bollin, Kathryn B; Carlino, Matteo S; Carvajal, Richard D; Cohen, Jonathan; Davar, Diwakar; Delman, Keith A; Dummer, Reinhard; Farwell, Michael D; Fisher, David E; Fusi, Alberto; Glitza, Isabella C; de Gruijl, Tanja D; Gyor... Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: e378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Issue 10336 (30th April 2022) Authors: Luke, Jason J; Rutkowski, Piotr; Queirolo, Paola; Del Vecchio, Michele; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; de la Cruz Merino, Luis; Khattak, Muhammad A; Schadendorf, Dirk; Long, Georgina V; Ascierto, Paolo A; Mandala, Mario; De Galitiis, Federica; Haydon, Andrew; Dummer, Reinhard; Grob, J... Journal: Lancet Issue: Volume 399:Issue 10336(2022) Page Start: 1718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗